文献速递艾滋病与性传播感染真菌感染新发突发、热带与寄生虫病

巨细胞病毒血症与撒哈拉以南非洲隐球菌脑膜炎患者死亡率升高相关

Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该前瞻性队列纳入2010—2012年乌干达111例合并隐球菌脑膜炎的HIV感染者,检测基线血浆CMV DNA并比较10周生存率。52%可检出CMV DNA,CMV血症者10周死亡率为40%,无CMV血症者为21%,校正后死亡风险仍显著升高;CMV血症与死亡相关还是免疫功能障碍的标志尚不明确。

要点

  • 合并隐球菌脑膜炎的晚期AIDS患者中约半数可检出CMV血症。
  • CMV血症者10周死亡率40%,无CMV血症者21%,校正后风险仍升高。
  • CMV血症是死亡相关标志还是直接病因尚不明确。

核心结论

  • 在晚期HIV/AIDS合并隐球菌脑膜炎患者中,可检出CMV血症者10周死亡率显著高于无CMV血症者,校正已知死亡危险因素后关联仍显著。
  • CMV血症反映直接致病作用还是潜在免疫功能障碍尚不明确(因果与伴随现象未定)。

研究设计与样本

  • 前瞻性队列研究,2010—2012年在乌干达纳入111例合并隐球菌脑膜炎的HIV感染者。
  • 对储存的基线血浆样本检测CMV DNA,比较有无CMV血症者的10周生存率。
  • 临床试验注册号NCT01075152。

主要发现

  • 111例中52%(58/111)可检出CMV DNA,中位血浆病毒载量498 IU/mL(IQR 259-2390)。
  • 所有受检样本IgG血清学均为阳性;中位CD4+ T细胞计数19 cells/µL(IQR 9-70),有无CMV血症者间无差异(P = .47)。
  • 10周死亡率:CMV血症者40%(23/58),无CMV血症者21%(11/53), hazard ratio 2.19(95%CI 1.07-4.49;P = .03)。
  • 多因素校正已知死亡危险因素后, adjusted hazard ratio 3.25(95%CI 1.49-7.10;P = .003)。
  • 血清与脑脊液细胞因子水平及隐球菌抗原特异性免疫刺激反应在两组间总体相似。

临床怎么用

  • 对晚期HIV/AIDS合并隐球菌脑膜炎患者,可考虑关注CMV血症作为死亡风险分层信息。
  • CMV血症的临床意义及是否需针对性干预尚待进一步研究,不能据此直接推定抗CMV治疗获益。

局限性

  • 样本量111例,来自乌干达单一地区人群,外推需谨慎。
  • 仅检测基线储存血浆CMV DNA,未动态监测CMV血症变化。
  • 观察性设计无法区分CMV血症与死亡的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cryptococcal meningitis and tuberculosis are both important causes of death in persons with advanced human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Cytomegalovirus (CMV) viremia may be associated with increased mortality in persons living with HIV who have tuberculosis. It is unknown whether concurrent CMV viremia is associated with mortality in other AIDS-related opportunistic infections. METHODS: We prospectively enrolled Ugandans living with HIV who had cryptococcal meningitis from 2010-2012. Subsequently, we analyzed stored baseline plasma samples from 111 subjects for CMV DNA. We compared 10-week survival rates among those with and without CMV viremia. RESULTS: Of 111 participants, 52% (58/111) had detectable CMV DNA (median plasma viral load 498 IU/mL, interquartile range [IQR] 259-2390). All samples tested were positive on immunoglobin G serology. The median CD4+ T cell count was 19 cells/µL (IQR 9-70) and did not differ by the presence of CMV viremia (P = .47). The 10-week mortality rates were 40% (23/58) in those with CMV viremia and 21% (11/53) in those without CMV viremia (hazard ratio 2.19, 95% confidence interval [CI] 1.07-4.49; P = .03), which remained significant after a multivariate adjustment for known risk factors of mortality (adjusted hazard ratio 3.25, 95% CI 1.49-7.10; P = .003). Serum and cerebrospinal fluid cytokine levels were generally similar and cryptococcal antigen-specific immune stimulation responses did not differ between groups. CONCLUSIONS: Half of persons with advanced AIDS and cryptococcal meningitis had detectable CMV viremia. CMV viremia was associated with an over 2-fold higher mortality rate. It remains unclear whether CMV viremia in severely immunocompromised persons with cryptococcal meningitis contributes directly to this mortality or may reflect an underlying immune dysfunction (ie, cause vs effect). CLINICAL TRIALS REGISTRATION: NCT01075152.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Skipper C, Schleiss MR, Bangdiwala AS, et al. Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa. Clin Infect Dis. 2020. PMID: 31504335. doi:10.1093/cid/ciz864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。